113 related articles for article (PubMed ID: 30765642)
1. [Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2019 Jan; 46(1):50-53. PubMed ID: 30765642
[No Abstract] [Full Text] [Related]
2. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
3. ["... and now about the costs!"].
Rohde D
Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
[No Abstract] [Full Text] [Related]
4. The Authors Respond.
Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
[No Abstract] [Full Text] [Related]
5. The Authors Respond.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; El Khoury MH
J Manag Care Spec Pharm; 2015 Sep; 21(9):836-40. PubMed ID: 26536676
[No Abstract] [Full Text] [Related]
6. Advanced renal cell carcinoma in Australia, 2015: what should we do?
Davis ID
Asia Pac J Clin Oncol; 2014 Dec; 10(4):285-8. PubMed ID: 25392943
[No Abstract] [Full Text] [Related]
7. Welcome clinical leadership at NICE.
Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
[No Abstract] [Full Text] [Related]
8. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
9. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
Eisen T
BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
[No Abstract] [Full Text] [Related]
10. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
12. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
14. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
Elsada A; Adler AI
Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
[No Abstract] [Full Text] [Related]
15. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.
Vrdoljak E; Torday L; Szczylik C; Kharkevich G; Bavbek S; Sella A
Expert Opin Pharmacother; 2016; 17(1):93-104. PubMed ID: 26619144
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Drug Ther Bull; 2011 Nov; 49(11):129-32. PubMed ID: 22074946
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):255-265. PubMed ID: 29448845
[TBL] [Abstract][Full Text] [Related]
18. Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2.
Laguna MP
J Urol; 2016 Mar; 195(3):608. PubMed ID: 26887702
[No Abstract] [Full Text] [Related]
19. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Geynisman DM; Hu JC; Liu L; Tina Shih YC
Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
